Xencor (XNCR) Projected to Post Earnings on Wednesday

Xencor (NASDAQ:XNCR) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Xencor to announce earnings of ($0.84) per share and revenue of $18.8890 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The firm had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. Xencor’s quarterly revenue was down 86.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.66) earnings per share. On average, analysts expect Xencor to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Xencor Trading Up 0.6%

Shares of NASDAQ:XNCR opened at $19.97 on Wednesday. The firm has a 50 day moving average of $14.32 and a 200-day moving average of $13.01. Xencor has a 12 month low of $6.92 and a 12 month high of $21.26. The stock has a market capitalization of $1.48 billion, a PE ratio of -8.72 and a beta of 0.86.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Truist Financial lowered their target price on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.

Institutional Investors Weigh In On Xencor

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc increased its holdings in Xencor by 603.7% in the 3rd quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock worth $14,932,000 after purchasing an additional 1,092,095 shares in the last quarter. State Street Corp boosted its stake in shares of Xencor by 22.7% during the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after purchasing an additional 833,423 shares in the last quarter. RTW Investments LP boosted its stake in shares of Xencor by 8.9% during the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock valued at $103,763,000 after purchasing an additional 556,407 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Xencor by 94.5% during the second quarter. Bank of America Corp DE now owns 938,993 shares of the biopharmaceutical company’s stock worth $7,380,000 after purchasing an additional 456,302 shares during the last quarter. Finally, Toronto Dominion Bank grew its holdings in shares of Xencor by 882.0% during the fourth quarter. Toronto Dominion Bank now owns 491,000 shares of the biopharmaceutical company’s stock worth $7,517,000 after purchasing an additional 441,000 shares during the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.